TICKERNERD
Menu
MDWDMDWDHealthcare · Biotechnology

MDWD Stock Forecast: MediWound Ltd. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$13
+1.05% on the day

The 6 Wall Street analysts covering MediWound Ltd. hold a median 12-month price target of $30 — +139.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$160.3M
Ticker Nerd rank
29 / 100
Median analyst target
$30
Analysts covering
6
Revenue$3.1M−45.8% y/y
Operating income−$9.5M
Net income−$7.4M
Free cash flow−$10.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
−9.3%
YTD
−32.0%
1Y
−29.9%
From 52W high
−36.3%
From 52W low
+1.0%
$12
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDWD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MediWound Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
94
Size
70
Revisions
61
Growth
52
Value
28
Momentum
28
Accruals
25
Issuance
23
Quality
21

Volatility (94): The share price has been relatively steady.

Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDWD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDWD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26MDWDHigh $36Median $30Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $25Median $30High $36

The green dot is the last close — the median target sits +139.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026OppenheimerMaintainsOutperform$32 → $30
28 May 2026HC Wainwright & Co.ReiteratesBuy$36
28 May 2026HC Wainwright & Co.ReiteratesBuy—
28 May 2026OppenheimerMaintainsOutperform$33 → $32
28 May 2026OppenheimerMaintainsOutperform—
21 Nov 2025HC Wainwright & Co.MaintainsBuy—
22 May 2025HC Wainwright & Co.MaintainsBuy—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025Craig-HallumInitiatesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.MaintainsBuy—
11 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
16 July 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
16 Jan 2024HC Wainwright & Co.MaintainsBuy—
22 Nov 2023HC Wainwright & Co.ReiteratesBuy—
21 Sept 2023HC Wainwright & Co.MaintainsBuy—
17 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDWD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MDWD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Oct 2026, MediWound Ltd. returned −29.9% against +17.3% for the S&P 500, dividends included.

MDWD vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26MDWDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDWD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

MediWound Ltd. (MDWD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 91% of US stocks

Price / sales
13.8×

Cheaper than 11% of US stocks

Price / book
4.6×

Cheaper than 21% of US stocks

EV / EBITDA
−4.3×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−45.8%

Higher than 6% of US stocks

Earnings growth (YoY)
−45.8%

Higher than 12% of US stocks

Gross margin
10.9%

Higher than 10% of US stocks

Operating margin
−305.9%

Higher than 9% of US stocks

Net margin
−170.1%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−72.4%

Higher than 17% of US stocks

Return on assets
−28.6%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MediWound Ltd. (MDWD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MediWound Ltd. has a market value of $160.3M and an enterprise value of $133.6M.

  • Revenue in the twelve months to 30 June 2026: $11.9M. The latest quarter shrank 45.8% year on year.

  • Net income over the same four quarters: −$20.2M, a −170.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.80.

  • Free cash flow in the twelve months to 30 June 2026: −$28.5M.

  • Shares outstanding: 12.9M.

  • Trailing P/E: −5.9×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • MediWound Ltd. employs 121 people — $98K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

MDWD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDWDMediWound Ltd.$160.3M
29
CNTNCanton Strategic Holdings, Inc.$160.4M
11
CHRSCoherus Oncology, Inc.$159.9M
49
VRXAVERAXA Biotech AG$161.0M
23
CUECue Biopharma, Inc.$162.2M
36
NKTXNkarta, Inc.$158.3M
43
ALXOALX Oncology Holdings, Inc.$163.2M
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MediWound Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDWD news & analysis

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

GlobeNewsWire · 22 Sept 2026positive

MediWound received an additional $3.3 million from the U.S. Department of War to advance work on a room-temperature-stable formulation of NexoBrid. This funding supports ongoing development of the product.

Why it matters — Additional government funding signals continued official support and progress toward a more convenient formulation of MediWound's flagship product, NexoBrid.

Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification

GlobeNewsWire · 14 Sept 2026positive

MediWound announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended that the study continue without modification, with no safety concerns identified. Interim assessment and enrollment completion remain on track for the end of the first quarter of 2027.

Why it matters — For MDWD watchers, a clean DSMB safety review and on-track timeline for the pivotal Phase III VALUE study represent a positive clinical development milestone for the EscharEx program.

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 2 Sept 2026neutral

MediWound Ltd. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made from the company's headquarters in Yavne, Israel.

Why it matters — An MDWD watcher would care because presenting at a major investment conference gives the company a platform to communicate with investors and the broader financial community.

MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

MediWound Ltd. held its second-quarter 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The item confirms the call took place and provides access to the company's discussion of its quarterly results.

Why it matters — MDWD watchers can review management's commentary on the company's Q2 2026 performance and outlook directly from the transcript.

MediWound Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026negative

MediWound reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier. The company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.

Why it matters — MDWD watchers would care because the lower quarterly revenue and ongoing spending on the Phase III EscharEx and NexoBrid programs signal the company's current financial position and its continued focus on advancing its pipeline development.

FAQ

Frequently asked questions about MDWD stock

What is the MDWD stock price forecast for 2026-2027?

The 6 Wall Street analysts covering MediWound Ltd. have a median 12-month price target of $30, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDWD stock a buy right now?

Of the 6 analysts covering MediWound Ltd., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediWound Ltd. 29 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDWD?

As at 8 Oct 2026, MediWound Ltd. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).

Will MDWD stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +139.0% from the last close, and Ticker Nerd's factor model ranks MediWound Ltd. 29 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDWD stock forecast for 2030?

No analyst covering MediWound Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.

How has MDWD stock performed over the past year?

MediWound Ltd. returned -29.9% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MediWound Ltd. do?

MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair.

What is the latest news on MDWD?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®". MediWound received an additional $3.3 million from the U.S. Department of War to advance work on a room-temperature-stable formulation of NexoBrid. This funding supports ongoing development of the product.

Company

About MediWound Ltd.

MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair. MediWound develops, manufactures, and commercializes products designed to address severe burns, chronic wounds, and other hard-to-heal tissue injuries. Its portfolio centers on biologic and protein-based treatments that selectively remove damaged tissue while preserving healthy tissue, supporting cleaner wound bed preparation and recovery care. The company serves hospitals, burn centers, and other healthcare providers involved in acute and specialized wound management. MediWound also works across tissue regeneration and related therapeutic areas, positioning itself within the broader wound care and regenerative medicine market. Headquartered in Yavne, Israel, MediWound emphasizes advanced, clinically focused solutions that aim to improve treatment workflows in modern wound care settings.

121 employees · Israel · https://www.mediwound.com